Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Introduction to Hemostasis01:05

Introduction to Hemostasis

14.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.2K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacogenomics and Placebo Response in a Randomized Clinical Trial in Asthma.

Clinical pharmacology and therapeutics·2019
Same author

Developing new drug treatments in the era of network medicine.

Clinical pharmacology and therapeutics·2012
Same author

Detection of nitrosated proteins.

Current protocols in toxicology·2012
Same author

Cellular hypomethylation is associated with impaired nitric oxide production by cultured human endothelial cells.

Amino acids·2011
Same author

The antithrombotic effects of organic nitrates.

Trends in cardiovascular medicine·2011
Same author

New directions in thrombolytic therapy Molecular mutants and biochemical conjugates.

Trends in cardiovascular medicine·2011

Related Experiment Video

Updated: May 1, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Tissue plasminogen activator promotes platelet disaggregation in plasma.

J Loscalzo, D E Vaughan

    The Journal of Clinical Investigation
    |June 1, 1987
    PubMed
    Summary

    Tissue-type plasminogen activator (t-PA) promotes human platelet disaggregation by selectively breaking down cohesive fibrinogen. This mechanism may help dissolve blood clots and circulating platelet aggregates.

    Area of Science:

    • Biochemistry
    • Hematology
    • Thrombosis Research

    Background:

    • Platelet aggregation is a key process in thrombosis.
    • Tissue-type plasminogen activator (t-PA) is a crucial enzyme in fibrinolysis.
    • The role of t-PA in direct platelet disaggregation is not fully understood.

    Purpose of the Study:

    • To investigate the mechanism by which t-PA induces human platelet disaggregation.
    • To determine the role of fibrinogen in t-PA-mediated platelet disaggregation.
    • To explore the implications of t-PA's action on platelet aggregates in thrombolysis.

    Main Methods:

    • Induction of platelet aggregation using adenosine 5'-diphosphate in human plasma.
    • Treatment of platelet suspensions with t-PA and measurement of disaggregation.

    More Related Videos

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
    09:13

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

    Published on: April 6, 2017

    11.3K
    A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
    09:42

    A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

    Published on: June 4, 2021

    3.2K

    Related Experiment Videos

    Last Updated: May 1, 2026

    Ferric Chloride-induced Murine Thrombosis Models
    10:37

    Ferric Chloride-induced Murine Thrombosis Models

    Published on: September 5, 2016

    21.9K
    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
    09:13

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

    Published on: April 6, 2017

    11.3K
    A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
    09:42

    A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

    Published on: June 4, 2021

    3.2K
  • Analysis of fibrinogen proteolysis rates in platelet-bound and ambient forms.
  • Assessment of the effects of aspirin and alpha-2-antiplasmin on t-PA-induced disaggregation.

    • Main Results:

    • t-PA promoted the disaggregation of human platelets in plasma.
    • Disaggregation was facilitated by the addition of fresh plasma or fibrinogen.
    • Aspirin treatment enhanced t-PA's disaggregatory effect, while alpha-2-antiplasmin inhibited it.
    • Proteolysis of platelet-bound fibrinogen was kinetically faster than that of ambient fibrinogen.

    Conclusions:

    • t-PA facilitates platelet disaggregation via kinetically selective plasmin-mediated proteolysis of cohesive fibrinogen.
    • This mechanism suggests a dual role for thrombolytic agents in managing platelet thrombi and circulating aggregates.
    • Understanding t-PA's interaction with platelets offers insights into novel therapeutic strategies for thrombotic disorders.